Sinovac faces Nasdaq noncompliance over late 2025 filing

Sinovac Biotech Ltd. reports that Nasdaq has notified the company it is not in compliance with Listing Rule 5250(c)(2) because it failed to timely file a Form 6-K with interim financial statements for the second quarter of 2025.

Rhea-AI Filing Summary

Sinovac Biotech Ltd. reports that Nasdaq has notified the company it is not in compliance with Listing Rule 5250(c)(2) because it failed to timely file a Form 6-K with interim financial statements for the second quarter of 2025.

Sinovac previously received a Nasdaq staff delisting determination in November 2025 and has appealed. A Nasdaq Hearings Panel will consider both the earlier delisting determination and this new late-filing issue at a hearing scheduled for January 8, 2026, where Sinovac plans to present a plan aimed at maintaining its Nasdaq listing.

Positive

• None.

Negative

• Heightened Nasdaq listing risk: Sinovac is formally noncompliant with Nasdaq Listing Rule 5250(c)(2) due to a missing Q2 2025 Form 6-K and is already contesting a prior delisting determination, with both matters now before a Nasdaq Hearings Panel.

Insights

Equity & Listing Standards Analyst

Nasdaq noncompliance and prior delisting notice heighten listing risk for Sinovac.

Sinovac discloses that Nasdaq has formally deemed it noncompliant with Listing Rule 5250(c)(2) for not filing a Form 6-K with second-quarter 2025 interim financials. This comes on top of a Nasdaq staff delisting determination issued in November 2025, which the company has already appealed.

The combined issues will be reviewed by a Nasdaq Hearings Panel at a hearing on January 8, 2026. Sinovac states it intends to present its plan and views with the objective of maintaining its Nasdaq listing. Actual outcomes will depend on the panel’s assessment of the company’s compliance plan and progress on its delayed reporting.

For investors, the key near-term milestone is the Nasdaq hearing on January 8, 2026, where the panel will consider both the delisting determination and the new late-filing notification together.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq issue did Sinovac Biotech Ltd. (SVA) disclose in this 6-K?

Sinovac disclosed that Nasdaq notified the company it is not in compliance with Listing Rule 5250(c)(2) because it did not timely file a Form 6-K containing interim financial statements for the second quarter of 2025, triggering an additional listing concern alongside an existing delisting determination.

Why is Sinovac Biotech Ltd. (SVA) at risk of Nasdaq delisting?

Sinovac previously received a Nasdaq staff delisting determination in November 2025 and now faces a separate noncompliance notice for failing to timely file its 2025 half-year interim financial statements on Form 6-K, putting its continued Nasdaq listing under review by a Nasdaq Hearings Panel.

When will Nasdaq review Sinovac Biotech Ltd.’s (SVA) listing status?

Nasdaq’s Hearings Panel is scheduled to review Sinovac’s situation on January 8, 2026. At that hearing, the panel will consider both the earlier staff delisting determination and the new late-filing notification together, after Sinovac presents its plan and views on maintaining its Nasdaq listing.

What specific filing did Sinovac Biotech Ltd. (SVA) fail to submit on time?

Sinovac failed to timely submit a Form 6-K that should have contained an interim balance sheet and income statement as of the end of its second quarter of 2025. Nasdaq cited this missing interim financial report as the basis for noncompliance with Listing Rule 5250(c)(2).

How is Sinovac Biotech Ltd. (SVA) responding to Nasdaq’s noncompliance notice?

Sinovac states it is evaluating Nasdaq’s notification letter and intends to present its plan and views to the Nasdaq Hearings Panel at the January 8, 2026 hearing, with the stated objective of maintaining its Nasdaq listing despite the late-filing and prior delisting determination issues.

Does Sinovac Biotech Ltd. (SVA) mention its broader business in this disclosure?

Yes. Sinovac reiterates it is a China-based global biopharmaceutical company focused on vaccines for diseases such as influenza, hepatitis, varicella, polio, and COVID-19, highlighting products like CoronaVac and several WHO-prequalified vaccines as part of its diversified commercial portfolio and development pipeline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 03:23 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-32371

SINOVAC BIOTECH LTD.

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINOVAC BIOTECH LTD.
	By:	/s/ Andrew Y. Yan
	Name:	Andrew Y. Yan
	Title:	Chairman of the Board

Date: January 4, 2026

1

Exhibit Index

Exhibit 99.1		Press Release – Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Exhibit 99.2		Press Release - SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

2

Exhibit 99.1

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

BEIJING — Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025.

As previously disclosed, the Company received a delisting determination letter (the “Staff Determination”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present its views regarding this matter.

The Company is evaluating the Notification Letter and intends to present its plan and views to the Nasdaq Hearings Panel at the scheduled hearing with the objective of maintaining its Nasdaq listing.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s or Board’s control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu®), the world’s first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.

Contacts

Investor and Media Contact

Sinovac Biotech Ltd.

Email: ir@sinovac.com